Literature DB >> 8647364

-Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma-.

J Radke1, D Schmidt, M Böhme, U Schmidt, W Weise, J Morenz.   

Abstract

The concentrations of various cytokines were examined by ELISA in blood and in ascites from 14 patients with advanced ovarian cancer (stage IV). The control group consisted of 6 patients with benign gynaecological disorders. Compared with patients with benign gynaecological disorders, ascites and/or plasma of patients with ovarian cancer showed significantly higher levels of IL-6, IL-8, IL-10, TNF-alpha, and sIL-2R. There were no increases of IL-1 alpha, IL-1 beta, IL-2, IFN-gamma, and sCD14 levels. The possible pathogenetic significance of cytokines in ovarian cancer is discussed.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8647364     DOI： 10.1055/s-2007-1022247

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN： 0016-5751            Impact factor:   2.915


  9 in total

1.  Clinical implication of serum sIL-2R levels in ovarian cancer.

Authors:  S Wang; G Cai; Y Lu
Journal:  J Tongji Med Univ       Date:  1998

2.  The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer.

Authors:  Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  J Ovarian Res       Date:  2010-01-18       Impact factor: 4.234

3.  The Lipidomic Analyses in Low and Highly Aggressive Ovarian Cancer Cell Lines.

Authors:  Zhenwen Zhao; Qingchun Cai; Yan Xu
Journal:  Lipids       Date:  2015-12-10       Impact factor: 1.880

4.  Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients.

Authors:  Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  BMC Cancer       Date:  2011-05-30       Impact factor: 4.430

5.  Immunohistochemical staining of tumor necrosis factor-α and interleukin-10 in benign and malignant ovarian neoplasms.

Authors:  Millena Prata Jammal; Allison Araújo DA Silva; Agrimaldo Martins Filho; Eliângela DE Castro Côbo; Sheila Jorge Adad; Eddie Fernando Candido Murta; Rosekeila Simões Nomelini
Journal:  Oncol Lett       Date:  2014-12-08       Impact factor: 2.967

Review 6.  Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review.

Authors:  Locke D Uppendahl; Carly M Dahl; Jeffrey S Miller; Martin Felices; Melissa A Geller
Journal:  Front Immunol       Date:  2018-01-05       Impact factor: 7.561

Review 7.  The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer.

Authors:  Sudha S Savant; Shruthi Sriramkumar; Heather M O'Hagan
Journal:  Cancers (Basel)       Date:  2018-07-30       Impact factor: 6.639

8.  Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.

Authors:  Nicola Aceto; Stephan Duss; Gwen MacDonald; Dominique S Meyer; Tim-C Roloff; Nancy E Hynes; Mohamed Bentires-Alj
Journal:  Breast Cancer Res       Date:  2012-10-12       Impact factor: 6.466

Review 9.  Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer.

Authors:  Soochi Kim; Boyun Kim; Yong Sang Song
Journal:  Cancer Sci       Date:  2016-08-16       Impact factor: 6.716
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.